[Ivosidenib in the treatment of patients with cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy]

Bull Cancer. 2023 Dec;110(12):1230-1231. doi: 10.1016/j.bulcan.2023.05.003. Epub 2023 Sep 11.
[Article in French]
No abstract available

Keywords: Cholangiocarcinoma; Cholangiocarcinome; IDH1; Ivosidenib; Ivosidénib; Médecine de précision; Precision medicine.

Publication types

  • Letter

MeSH terms

  • Bile Duct Neoplasms* / drug therapy
  • Bile Duct Neoplasms* / genetics
  • Bile Ducts, Intrahepatic
  • Cholangiocarcinoma* / drug therapy
  • Cholangiocarcinoma* / genetics
  • Humans
  • Isocitrate Dehydrogenase / genetics
  • Leukemia, Myeloid, Acute* / genetics
  • Mutation

Substances

  • ivosidenib
  • IDH1 protein, human
  • Isocitrate Dehydrogenase